Biologics Approvals Face Orphan Issues In Early 1999; Nine Cleared In 1998
Two FDA decisions about biologics applications in line for early approval in 1999, ReFacto and Rebif, could hinge on orphan exclusivity deliberations.
You may also be interested in...
Amgen's Infergen has expanded its labeling for use in the subsequent treatment of hepatitis C patients who relapse following initial treatment with interferon alfa-2b or Infergen.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011